High-density lipoprotein inversely relates to its specific autoantibody favoring oxidation in thrombotic primary antiphospholipid syndrome

Abstract

Abnormalities of the lipid profile partly explain the atherogenic tendency of systemic lupus erythematosus but the picture is unclear in thrombotic primary antiphospholipid syndrome (PAPS). Herein we compare the lipid profile, high-density lipoprotein (HDL), low-density lipoprotein (LDL), total cholesterol (CHO), apolipoprotein A (ApoA-I), apolipoprotein B (ApoB), tryglicerides (TRY)), anti-lipoprotein antibodies, beta-2-glycoprotein I complexed to oxidized low-density lipoprotein (oxLDL-ß₂GPI) and C-reactive protein (CRP) from thrombotic PAPS (n = 34), thrombotic patients with inherited thrombophilia (IT; n = 36), subjects persistently positive for antiphospholipid antibodies (aPL, n = 18) with no underlying autoimmune or non-autoimmune disorders and healthy controls (n = 28) and determined the reciprocal effects of anti-lipoprotein antibodies, the lipid profile, oxLDL-ß₂GPI and CRP. Average concentrations of HDL (p < 0.0001), LDL (p < 0.0001), CHO (p = 0.0002), ApoA-I (p = 0.002) were lower in PAPS whereas average TRY was higher (p = 0.01) than other groups. Moreover, the aPL and PAPS group showed higher levels of IgG anti-HDL (p = 0.01) and IgG anti-ApoA-I (p < 0.0001) whereas the PAPS group showed greater average oxLDL-ß₂GPI (p = 0.001) and CRP (p = 0.003). Within the PAPS group, IgG anti-HDL correlated negatively to HDL (p = 0.004) and was an independent predictor of oxLDL-ß2GPI (p = 0.009). HDL and ApoA-I correlated negatively with CRP (p = 0.001 and p = 0.007, respectively). IgG anti-HDL may hamper the antioxidant and anti-inflammatory effect of HDL favoring low-grade inflammation and enhanced oxidation in thrombotic PAPS. Lupus (2010) 19, 711—716.

Keywords

antiphospholipid syndrome high-density lipoprotein

Get full access to this article

View all access options for this article.

References

Westerweel PE , Luyten RK , Koomans HA , Derksen RH , Verhaar MC Premature atherosclerotic cardiovascular disease in systemic lupus erythematosus. Arthritis Rheum 2007; 56: 1384-1396.

Ames PRJ , Antinolfi I. , Scenna G. , Gaeta G. , Margaglione M. , Margarita A. Atherosclerosis in thrombotic primary antiphospholipid syndrome. J Thromb Haemost 2009; 7: 537-542.

Matsuura E. , Hughes GR , Khamashta MA Oxidation of LDL and its clinical implication . Autoimmun Rev 2008; 7: 558-566.

Navab M. , Reddy S. , Van Lenten BJ , Anantharamaiah GM , Fogelman AM Role of dysfunctional HDL in atherosclerosis. J Lipid Res 2009; 50(Suppl): S145-S149.

Delgado Alves J. , Ames PR , Donohue S. , et al. Antibodies to high-density lipoprotein and beta2-glycoprotein I are inversely correlated with paraoxonase activity in systemic lupus erythematosus and primary antiphospholipid syndrome. Arthritis Rheum 2002; 46: 2686-2694.

Miyakis S. , Lockshin MD , Atsumi T. , et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306.

Deguchi H. , Pecheniuk NM , Elias DJ , Averell PM , Griffin JH High-density lipoprotein deficiency and dyslipoproteinemia associated with venous thrombosis in men. Circulation 2005 ; 112: 893-899.

Eichinger S. , Pecheniuk NM , Hron G. , et al. High-density lipoprotein and the risk of recurrent venous thromboembolism. Circulation 2007; 115: 1609-1614.

de Souza AW , Silva NP , de Carvalho JF , D’Almeida V. , Noguti MA , Sato EI Impact of hypertension and hyperhomocysteinemia on arterial thrombosis in primary antiphospholipid syndrome. Lupus 2007 ; 10: 782-787.

10.

Der H. , Kerekes G. , Veres K. , et al. Impaired endothelial function and increased carotid intima-media thickness in association with elevated von Willebrand antigen level in primary antiphospholipid syndrome. Lupus 2007; 16: 497-503.

11.

Jiménez S. , García-Criado MA , Tàssies D. , et al. Preclinical vascular disease in systemic lupus erythematosus and primary antiphospholipid syndrome. Rheumatology 2005; 44: 756-761.

12.

Bećarević M. , Andrejević S. , Miljić P. , Bonaci-Nikolić B. , Majkić - Singh N. Serum lipids and anti-oxidized LDL antibodies in primary antiphospholipid syndrome. Clin Exp Rheumatol 2007; 25: 361-366.

13.

Bilora F. , Boccioletti V. , Girolami B. , et al. Are antiphospholipid antibodies an independent risk factor for atherosclerosis? Clin Appl Thromb Hemost 2002 ; 8: 103-113.

14.

Kobayashi K. , Kishi M. , Atsumi T. , et al. Circulating oxidized LDL forms complexes with 2-glycoprotein I: implication as an atherogenic autoantigen. J Lipid Res 2003; 44: 716-717.

15.

Ames PR , Antinolfi I. , Ciampa A. , et al. Primary antiphospholipid syndrome: a low-grade auto-inflammatory disease? Rheumatology 2008; 47: 1832-1837.

16.

Medina G. , Casaos D. , Jara LJ , et al. Increased carotid artery intima-media thickness may be associated with stroke in primary antiphospholipid syndrome. Ann Rheum Dis 2003; 62: 607-610.

17.

de Carvalho JF , Borba EF , Viana VS , Bueno C. , Leon EP , Bonfá E.

Anti-lipoprotein lipase antibodies: a new player in the complex atherosclerotic process in systemic lupus erythematosus?

Arthritis Rheum 2004; 50: 3610-3615.

18.

Kontush A. , Chapman JM Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis . Pharmacol Rev 2006; 58: 342-374.